Drugs / 177Lu-3BP-227
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03525392 | May 2018 → Apr 2020 | bone cancer, colorectal cancer, gastric cancer, head and neck squamous cell carcinoma +2 | Ipsen | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-3BP-227 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03525392 ↗ |
| Route | Intravenous | “administered in two intravenous (i.v.) infusions” NCT03525392 ↗ |